Does Adamas Pharmaceuticals Inc (ADMS) Have Any Gas After Forming This Bullish Descending Triangle Chart Pattern?

July 17, 2017 - By Kurt Siggers

The stock of Adamas Pharmaceuticals Inc (ADMS) formed a descending triangle with $17.64 target or 4.00 % above today’s $16.96 share price. The 6 months triangle pattern indicates low risk for the $379.89 million company. If the $17.64 price target is reached, the company will be worth $15.20 million more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 0.18% or $0.03 during the last trading session, reaching $16.96. About 60,205 shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since July 17, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Adamas Pharmaceuticals had 13 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, December 24 by Credit Suisse. On Thursday, June 16 the stock rating was upgraded by Mizuho to “Buy”. Cowen & Co initiated Adamas Pharmaceuticals Inc (NASDAQ:ADMS) on Tuesday, January 19 with “Outperform” rating. The rating was maintained by Mizuho with “Buy” on Thursday, September 8. The stock has “Buy” rating by Aegis Capital on Tuesday, September 22. Zacks downgraded Adamas Pharmaceuticals Inc (NASDAQ:ADMS) on Friday, August 7 to “Buy” rating. The firm has “Neutral” rating by Mizuho given on Thursday, April 28. Mizuho initiated the stock with “Neutral” rating in Tuesday, January 19 report. The rating was maintained by Mizuho with “Buy” on Tuesday, June 6. The firm earned “Neutral” rating on Thursday, May 12 by Mizuho.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Globenewswire.com which released: “Adamas Reports Inducement Grant to New Chief Operating Officer” on May 05, 2017, also Globenewswire.com with their article: “Adamas to Present at Two Upcoming Investor Conferences” published on June 01, 2017, Globenewswire.com published: “Adamas Announces New Employment Inducement Grant” on March 10, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Globenewswire.com and their article: “Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare …” published on May 11, 2017 as well as Globenewswire.com‘s news article titled: “Adamas Appoints Richard A. King as Chief Operating Officer to Lead …” with publication date: April 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.